Asthma ‐ childhood (incidence) · infants
It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Eczema ‐ childhood (incidence) · infants
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood (incidence) · infants
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Seizure freedom · patients with drug‐resistant epilepsy
PUFA may leads to higher seizure freedom compared with placebo (low certainty).
1 finding from 1 review
50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐ Older (19 years or more) · patients with drug‐resistant epilepsy
PUFA showed no clear difference in 50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐… compared with placebo (low certainty).
1 finding from 1 review
50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐ Younger (< 19 years) · patients with drug‐resistant epilepsy
PUFA may leads to higher 50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐… compared with placebo (low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · patients with drug‐resistant epilepsy
PUFA showed no clear difference in 50% reduction in seizures frequency (6 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Potential adverse effects ‐ not reported · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal effects · patients with drug‐resistant epilepsy
PUFA showed no clear difference in gastrointestinal effects compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Relapse rate at one year (all studies) · Crohn's disease patients in remission
It is very uncertain whether the intervention changes relapse rate at one year (all studies) (very low certainty).
1 finding from 1 review
Intervention not reported
Relapse rate at one year (sensitivity analysis of Belluzi 1996) · Crohn's disease patients in remission
It is very uncertain whether the intervention changes relapse rate at one year (sensitivity analysis of Belluzi 1996) (very low certainty).
1 finding from 1 review
Intervention not reported
Relapse rate at one year (only EPIC studies) · Crohn's disease patients in remission
The intervention showed no clear difference in relapse rate at one year (only EPIC studies) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events rate‐Diarrhea · Crohn's disease patients in remission
The intervention probably leads to higher adverse events rate‐Diarrhea (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events rate‐ Upper GI (nausea, vomiting, halitosis, heartburn, dyspepsia, dysgeusia and bloating) · Crohn's disease patients in remission
The intervention probably leads to higher adverse events rate‐ Upper GI (nausea, vomiting, halitosis,… (moderate certainty).
1 finding from 1 review